PharmX Technologies (ASX:PHX) FFO


ASX:PHX PharmX Technologies Ltd ASX:PHX
40 GF Score
Price A$0.13
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies FFO?

FFO (Funds from operations) only applies to REITs.

ASX:PHX
40GF Score
PharmX Technologies Ltd ASX:PHX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • FFO:
  • GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score

Get the complete analysis for ASX:PHX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.07
GF Value